Skin Cancer

Samer Wahood, AB, shares that his research reveals a significant link between July erythemal UV radiation exposure and increased risks of melanoma in situ and invasive melanoma.

Data come from patients with stage 3 melanoma enrolled in a phase 3 randomized trial and showed that detection of circulating tumor DNA (ctDNA) prior to adjuvant systemic therapy can predict risk of early recurrence.

Immediate local flap or skin graft following basal cell carcinoma (BCC) can be considered, a study found.

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

Investigators highlighted Raman spectroscopy, a noninvasive diagnostic technology that could lead to faster, earlier detection of skin cancer.

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.

The study could open the door to potential novel therapeutic targets.

Men with melanoma tend to be diagnosed later and have worse outcomes. Artificial intelligence can help change that, a review suggests.

A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

A topical treatment combining calcipotriol and 5-FU shows promise in reducing premalignant lesions and lowering skin cancer risk by activating Th2 immunity.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery.

However, metformin did not protect Black patients against squamous cell carcinoma specifically.

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.

The announcement followed the release of the RhodoLED XL red light-emitting lamp, to be used in combination with aminolevulinic acid hydrochloride topical gel, 10% for actinic keratoses.

Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

A poster presented at the 2024 American Society of Clinical Oncology annual meeting argued the benefits that Medicaid expansion can bring to patients with melanoma.

Two posters presented at the 2024 American Society of Clinical Oncology annual meeting revealed real-world data on the outcomes and management strategies associated with melanoma during pregnancy.

At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.

Metformin showed promise for improving the overall survival rate of patients with melanoma; however, this result may be an indirect consequence of the drug.

A large Medicare cohort study found that the most common locations of procedurally treated keratinocyte cancers in the US were the head and/or neck for both squamous cell carcinomas and basal cell carcinomas.